Clinical trial recruitment for ABBV-744 study Fundamentals Explained
In Phase C, members will obtain ABBV-744 and oral navitoclax. In Phase D, participants will obtain ABBV-744 and ruxolitinib. Contributors will obtain treatment right until ailment progression or the individuals are unable to tolerate the study drugs.- "Our study revealed the critical position with the KLF16/MYC regulatory axis in modulating tumor e